-
Verapamil HCl: Calcium Channel Research Guide
2026-09-11
Verapamil HCl is a phenylalkylamine L-type calcium channel blocker used to investigate calcium signaling, apoptosis, inflammation, and bone remodeling. Product data and a peer-reviewed osteoporosis study support defined handling conditions and mechanistic research applications, while cell and animal findings should not be interpreted as clinical efficacy.
-
NVP-BGJ398 Phosphate: FGFR Signal to Phenotype
2026-09-10
NVP-BGJ398 phosphate provides a mechanistic bridge between FGFR1–3 biology, biomarker-led oncology, and emerging skeletal-disease research. This thought-leadership perspective explains how to translate receptor inhibition into defensible experimental decisions while distinguishing promising preclinical signals from clinical evidence.
-
ABT-199: Designing Senescence-Aware Apoptosis Assays
2026-09-10
ABT-199 and Venetoclax can reveal BCL-2 dependence, but response timing is as important as concentration. This guide translates glioblastoma senescence findings into more discriminating apoptosis assay and hematologic malignancy research workflows.
-
Cabazitaxel (XRP6258) Workflow Guide
2026-09-09
Cabazitaxel (XRP6258) is a semi-synthetic taxane derivative for studying microtubule dynamics disruption in taxane-resistant, including P-glycoprotein-expressing, cancer models. This guide covers DMSO- or ethanol-based preparation, storage, 96-hour assay planning, and quality control; it should not be treated as a water-soluble reagent or as a substitute for paper-specific dosing or clinical guidance.
-
DRB for Transcriptional Elongation Workflows
2026-09-09
DRB provides an acute, tunable way to interrogate RNA polymerase II output, CDK-dependent transcription, and transcription-linked cell-fate transitions. Its value is greatest when paired with time-resolved RNA, protein, and condensate measurements rather than used as a pathway-specific readout alone.
-
Nerve-Mediated HDAC1 in Axolotl Limb Regeneration
2026-09-08
Wang and colleagues showed that nerve input controls a biphasic increase in HDAC1 during axolotl limb regeneration and that this response is required for blastema formation. Pharmacological inhibition, denervation, and nerve-factor supplementation together place HDAC1 activity at an important interface between the wound epidermis, neural signals, and regenerative tissue formation.
-
Zebrafish Mbd5 Links RNA m5C to Chromatin Control
2026-09-07
The 2024 Nucleic Acids Research study identifies zebrafish Mbd5 as an RNA m5C reader rather than a conventional methylated-DNA-binding protein. Its interaction with the PR-DUB complex connects modified RNA recognition to H2A-K119 deubiquitylation, with consequences for development, erythrocyte differentiation, iron metabolism, gene expression, and behavior.
-
CX-4945 (Silmitasertib) for Reliable Cell Assays
2026-09-07
A scenario-based guide to using CX-4945 (Silmitasertib), SKU A8330, for interpretable viability, apoptosis, proliferation, and cell-cycle experiments. It connects CK2 potency, formulation, assay controls, and vendor-selection considerations with cancer and neuroinflammation evidence.
-
N3-kethoxal Workflows for RNA and DNA Mapping
2026-09-05
N3-kethoxal converts exposed guanines into click-ready landmarks for RNA structure probing, accessible-DNA mapping, and nucleic acid interaction studies. This practical guide connects assay design with the emerging biology of NET-associated ssDNA and thrombin while emphasizing controls, optimization, and interpretation limits.
-
SIA-cIgG, PTPN13, and Cisplatin in HNSCC
2026-09-05
A 2026 study identifies the SIA-cIgG/PTPN13 axis as a regulator of tumor stemness and chemotherapy resistance in head and neck squamous cell carcinoma. Its combination of anti-SIA-cIgG treatment, standard chemotherapy, xenograft models, and patient-derived organoids provides a mechanistic and translational framework for improving CDDP response.
-
GKT137831: Dual Nox1/Nox4 Inhibitor Workflow
2026-09-04
Build more interpretable oxidative-stress experiments with GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor for vascular, fibrosis, and metabolic disease models. This guide combines dose planning, ROS and membrane-integrity readouts, translational applications, and troubleshooting while placing recent ferroptosis findings in the correct hypothesis-generating context.
-
B3465: α2-Adrenergic Receptor Agonist
2026-09-04
Explore how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine can support rigorous α2-adrenergic receptor signaling studies. This article focuses on assay design, immune-versus-tumor mechanisms, formulation constraints, and practical interpretation of osteosarcoma recurrence research.
-
Dacarbazine Assays: From DNA Damage to Cell Killing
2026-09-03
Turn Dacarbazine exposure into a more informative cancer assay by separating growth inhibition from true cell killing. This workflow combines time-resolved viability measurements, careful formulation, and model-specific interpretation for melanoma, lymphoma, and sarcoma research.
-
Y-27632 ROCK Inhibitor for Organoid Workflows
2026-09-02
Y-27632 provides a reversible, selective way to tune ROCK-dependent cytoskeletal behavior during cell recovery, organoid establishment, and imaging assays. This practical guide connects patient-derived colorectal organoid workflows with dose selection, washout controls, and troubleshooting strategies for more reproducible cancer biology research.
-
TIA1–CLSTN1 Splicing Axis in Breast Cancer
2026-09-02
A 2026 Oncogene study identifies a DAPK3–TIA1–CLSTN1 regulatory axis in which loss or phosphorylation-mediated inhibition of TIA1 increases CLSTN1 exon 11 inclusion and promotes breast cancer metastasis. Splice-switching antisense oligonucleotides reversed this event and reduced migration, providing a mechanistic and therapeutic framework for targeting pro-metastatic RNA splicing.